Guardant Health And Zephyr AI Partner To Accelerate Cancer Drug Discovery With AI-Driven DNA And Clinical Data Fusion

Author: Benzinga Newsdesk | October 27, 2025 07:10am

• Strategic partnership will link DNA data with rich clinical data to identify novel biomarkers for targeted cancer therapies
• The two companies will utilize AI and multimodal molecular data to unlock new insights for personalized oncology treatments

Guardant Health (NASDAQ:GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine harnessing artificial intelligence to accelerate drug development, today announced a strategic partnership to deliver novel, scalable, and actionable insights that support biopharmaceutical innovation. This collaboration will combine unique multimodal molecular data and AI/ML technology from both companies driving advancement of novel cancer biomarkers for drug development, targeted therapies selection, and response monitoring.

The partnership will be integrated with Guardant's broader suite of Infinity AI capabilities and exemplifies both companies' broader commitment to harnessing AI and multimodal data to empower oncologists, researchers, and biopharma developers with solutions to transform cancer patient care.

Posted In: GH